From Ebola, to MRSA, to HIV and SARS, over 300 infectious diseases have been discovered since the mid-20th century. With the advent of immunizations and antimicrobial drugs, it seemed for a short while that the global war against these diseases might be on the path to victory. Unfortunately, many infectious diseases which deemed all-but-eradicated just a few years ago, have now evolved into drug and antibiotic resistant strains. This presents the Global Cephalosporin Drugs market with a double-edged sword of both opportunity, and immense challenge.
To elaborate, the rampant wave of ”superbugs” offers a huge opening for vendors to enter the market with new innovative, effective drugs. However, the constant evolution of these infections also means that vendors run the risk of developing advanced treatments only to be forced to discard them if the disease is deemed drug-resistant.
Despite this risk, for vendors to stay afloat in the Global Cephalosporin Drugs Market it is absolutely critical that they focus their resources on introducing novel products to specifically combat antiobotic resistance. Key players such as GlaxoSmithKline, Hoffman-La Roche, and Abbot Laboratories, are already investing huge amounts into R and D to develop new antibiotics targeting:
- Methionine tRNA ligase inhibitors
- DNA topoisomerase II inhibitors
- Ribosomal inhibitors
- Cell wall synthesis inhibitors
The key is developing products with novel mechanisms of action that bacteria have never been exposed to, and the reward potential of this development is immeasurably high for vendors and end-users alike. Yes, companies competing in the Global Cephalosporin Drugs market stand to receive massive profits from the discovery of a successful treatment for the many antibiotic resistant diseases across the globe. Of even greater value however, are the millions of lives that will be saved worldwide once such a discovery is made.
For more info, view our 2012-2016 report on the Global Cephalosporin Drugs market.
Other Related Reports:
Global Alzheimer’s Drugs Market 2012-2016
Global Cardiovascular Drugs Market 2012-2016
